Looking for the right drug for the right patient: a tale of old drugs and new pathways.

Suppr

超能文献

作者信息

Alba Emilio, Ribelles Nuria

出版信息

Clin Transl Oncol. 2005 Oct;7(9):375-6. doi: 10.1007/BF02716582.

DOI:10.1007/BF02716582

PMID:16238971

Abstract

摘要

相似文献

Looking for the right drug for the right patient: a tale of old drugs and new pathways.

Clin Transl Oncol. 2005 Oct;7(9):375-6. doi: 10.1007/BF02716582.

Effectiveness of adjuvant fluorouracil in elderly colon cancer patients: the internal and external validity of nonrandomized research design.

J Clin Oncol. 2003 May 1;21(9):1892; author reply 1893. doi: 10.1200/JCO.2003.99.238.

Mature results of adjuvant colon cancer trials from the fluorouracil-only era.

J Natl Cancer Inst. 2004 May 19;96(10):727-9. doi: 10.1093/jnci/djh154.

Defective mismatch repair in colon cancer: a prognostic or predictive biomarker?

J Clin Oncol. 2010 Jul 10;28(20):3210-2. doi: 10.1200/JCO.2010.28.9322. Epub 2010 May 24.

Optimal duration of fluorouracil plus levamisole colon cancer surgical adjuvant therapy.

J Clin Oncol. 1996 Oct;14(10):2887.

[Photosensitization caused by 5-fluorouracil (5-FU)].

Schweiz Med Wochenschr. 1999 Jan 12;129(1-2):52.

High dose 5-fluorouracil (5-FU) and folinic acid in advanced colorectal cancer resistant to standard dose 5-FU treatment: results of a phase II study.

Eur J Cancer. 1995 Sep;31A(10):1717. doi: 10.1016/0959-8049(95)00238-e.

Selective inflammatory effect of systemic fluorouracil in actinic keratosis.

Cutis. 1999 Jul;64(1):43-4.

[Adjuvant therapy for colon cancer].

Dtsch Med Wochenschr. 2004 Oct 29;129(44):2366-71. doi: 10.1055/s-2004-835270.

[Adjuvant therapy of colon cancer soon in tablet form].

Krankenpfl J. 2005;43(4-6):139.

本文引用的文献

Capecitabine as adjuvant treatment for stage III colon cancer.

N Engl J Med. 2005 Jun 30;352(26):2696-704. doi: 10.1056/NEJMoa043116.

Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity.

J Clin Oncol. 2005 Mar 1;23(7):1365-9. doi: 10.1200/JCO.2005.06.219.

Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients.

Pharmacogenetics. 2004 Dec;14(12):785-92. doi: 10.1097/00008571-200412000-00001.

Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate.

J Natl Cancer Inst. 2004 Jan 21;96(2):134-44. doi: 10.1093/jnci/djh015.

Cancer pharmacogenetics.

Br J Cancer. 2004 Jan 12;90(1):8-11. doi: 10.1038/sj.bjc.6601487.

Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3700-4.

Fluorinated pyrimidines, a new class of tumour-inhibitory compounds.

Nature. 1957 Mar 30;179(4561):663-6. doi: 10.1038/179663a0.

Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.

Clin Cancer Res. 2003 May;9(5):1611-5.

5-fluorouracil: mechanisms of action and clinical strategies.

Nat Rev Cancer. 2003 May;3(5):330-8. doi: 10.1038/nrc1074.

Additional SNPs and linkage-disequilibrium analyses are necessary for whole-genome association studies in humans.

Nat Genet. 2003 Apr;33(4):518-21. doi: 10.1038/ng1128. Epub 2003 Mar 24.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验